KCM
OCUL icon

Knoll Capital Management’s Ocular Therapeutix OCUL Stock Holding History

Knoll Capital Management’s Portfolio OCUL Stock Details OCUL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-95,800
Closed -$814K – 39
2023
Q2 		$814K Hold
95,800
– – 0.99% 24
2023
Q1 		$505K Buy
+95,800
New +$455K 0.78% 24

Other funds holding OCUL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
SR
Summer Road West Palm Beach, Florida $142M AUM 43.61% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Knoll Capital Management's OCUL Position: Q1 2026 in Review

Knoll Capital Management held its Ocular Therapeutix (OCUL) position steady in Q1 2026 at 600,400 shares worth $5.09M. The position accounts for 2.82% of the portfolio, ranked #17.

Knoll Capital Management first reported a position in OCUL in Q1 2023 and has held it in 13 quarters since. The position peaked at $7.28M in Q4 2025. 269 funds tracked by Wall St. Rank hold OCUL as of Q1 2026.

  • Knoll Capital Management held 600,400 shares of Ocular Therapeutix worth $5.09M as of Q1 2026.
  • Knoll Capital Management left its Ocular Therapeutix share count unchanged in Q1 2026.
  • Ocular Therapeutix made up 2.82% of Knoll Capital Management's portfolio in Q1 2026, its #17 holding.
  • Knoll Capital Management first reported a position in Ocular Therapeutix in Q1 2023 and has held it in 13 quarters since.
  • Knoll Capital Management's Ocular Therapeutix position peaked at $7.28M in Q4 2025.
  • 269 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q1 2026.

Based on Knoll Capital Management's 13F filing for Q1 2026, filed 15 May 2026.